The biotechnology industry is defined by cutting edge discoveries, breakthrough therapies, and new research methods. ProSci is here to help you keep up. As a major player in Custom Antibody Development, it is our responsibility to remain up to date on all antibody news, and as your antibody supplier it’s our mission to educate you in the world of antibodies. To this end, ProSci has decided to provide our readers with a monthly round-up of the most pressing antibody news. This month includes breakthroughs in monoclonal development technology, HIV treatment with antibodies, and results from the newest clinical trials for multiple myeloma.

 Monoclonal Antibody binding to Protein

Monoclonal Antibody Production:

A team of chemical engineers from Cornell University partnered with New England Biolabs to bypass the immunization phase of monoclonal antibody development. Their recently published method, termed “Shuffle,” has been already widely published. Shuffle mimics the primary immune response in vitro and provides an “alternative to random point mutation for affinity maturation of human antibodies.” The novel process drastically reduces the production time of monoclonal antibodies, rivaling the natural human immune system and promises an accelerated means of production for future pharmaceutical products.

 

T Follicular Helper (TFH) Cells and HIV:

TFH cells induce B cell differentiation, which results in two B cell subtypes: plasma cells and memory cells. Furthermore, these cells guide B cells to produce antibodies with increased specificity through affinity maturation, which Takuya Yamamoto and his team have shown to be essential in the immune system’s fight against SHIV and HIV.  His research demonstrates the increased efficacy of vaccines against HIV that include agents that stimulate TFH  cells.

 

Antibodies Against Myeloma

The race towards novel FDA approved treatments is always fierce, but this month has proved to be especially competitive. The newest arena in which pharmaceutical giants are battling is the development of antibody drug therapies for Multiple Meyloma patients.

 

The contenders:

Johnson & Johnson and Genmab have been developing daratumumab, a monoclonal antibody against a transmembrane ectoenzyme called CD38, which is expressed on the surface of multiple myeloma cells. Currently the drug is in phase 5 of clinical trails and was pushed into the spotlight when J&J released a promising set of data indicating high efficacy of the treatment in patients with few other options.

 

Bristol-Myers Squibb partnered with AbbVie to produce elotuzumab, another monoclonal antibody, which targets a lymphocyte activation molecule named SLAMF7. Elotuzumab is currently in Phase 4 for of clinical trials but has been given an edge by the FDA, earning itself a 6-month evaluation process instead of the traditional 10.

 

To read more about big pharma dueling for a foothold in the market of cancer drugs, read up at FierceBiotech.

 

 

-Your Antibody Experts and News Source